| アブストラクト | BACKGROUND: Biologics are used to treat moderate-to-severe Crohn disease (CD). In Japan, ustekinumab was approved for reimbursement for CD treatment in 2017. However, limited information describes utilization of ustekinumab in real-world settings. OBJECTIVE: To describe treatment patterns and clinical outcomes of patients with CD treated with ustekinumab in Japan. METHODS: A retrospective cohort drug utilization study was conducted using the Japan Medical Data Center employment insurance database. Patients with a diagnosis of CD who initiated treatment with ustekinumab (International Classification of Disease, Tenth Revision [ICD-10] K50.x) from January 1, 2017, to September 30, 2020, were enrolled. Eligible patients were followed up until disenrollment or study end (September 30, 2020). RESULTS: A total of 622 patients with CD initiated ustekinumab during the study period; 45.7% had no prior history of biologic use (bio-naive) and 54.3% had previously received >/=1 biologic (bio-experienced); 82.8% of patients received an induction dose of whom 97.5% received a dose within the recommended range (260-520 mg) and 90.8% of patients received their first maintenance dose within a 42- to 70-day interval. Median treatment duration was 14.8 months and 90.2% remained on ustekinumab at study end. Compared with the 12-month period prior to ustekinumab initiation, surgical procedures decreased by 88.0%, gastrointestinal complications by 64.6%, enteral nutrition requirements by 41.9%, and CD-related hospitalizations by 62.6% within 12 months after commencing ustekinumab. CONCLUSIONS: These first real-world data from Japan, where ustekinumab has been used longest for CD treatment, shows that a majority of patients initiated ustekinumab as per the recommended label. Indirect evidence of clinical impact could be relevant in other settings in Asia. |
|---|
| ジャーナル名 | The Annals of pharmacotherapy |
|---|
| 投稿日 | 2023/1/6 |
|---|
| 投稿者 | Liu, Yanfang; Goh, Choo Hua; Qiu, Hong; Huang, Kuan-Chih; Chung, Hsingwen; Saadoun, Carine |
|---|
| 組織名 | Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Singapore.;Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Titusville,;NJ, USA.;Epidemiology, Office of the Chief Medical Officer, Johnson & Johnson, Taipei;City, Taiwan.;Office of the Chief Medical Officer, Johnson & Johnson, Titusville, NJ, USA.;Regional Medical Affairs, Janssen Asia Pacific, Singapore. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36602021/ |
|---|
